Preclinical Biopharmaceuticals

Our research focuses on the development of new drugs for the treatment of colon cancer, metabolic and neurodegenerative diseases.

VIEW CONTENT

Main Technology

Extraction of bioactive compounds, antioxidant, anti-proliferative and anti-inflammatory characterisation and potentiation of their effects using nanotechnology. As a result, we hold several patents with applications in the biomedical industry.

WHAT HAVE WE DISCOVERED

904019

DEFUNTIONS

FOR COLON-RECTAL CANCER*

*CancerToday, 2022

What we have discovered

New sources of plant extracts that have shown high antioxidant or anti-proliferative activity in various preclinical trials, both in vitro and in vivo.

At the moment CELLBITEC has patented so many plant extracts with a proven biofunctional capacity, as well as its extraction methodology and the isolation of several of these molecules by means of nanotechnology.

Cellbitec has several research projects funded through programmes of the European Union, the Ministry of Science, Innovation, Universities of the Spanish Government and the Carlos III Institute of Health together with the Centre for Technological Development and Innovation of Spain, where it continues to focus on the screening of new molecules in different plant genera and species, as well as the development of new drugs with the molecules already identified.

OUR RESULTS
OUR R&D PROJECTS

PHASES IN THE STUDY OF A MEDICINAL PRODUCT

DISCOVERY

  • PATENT

  • STRUCTURAL CLARIFICATION

  • ISOLATION

  • PURIFICATION

  • TAXONOMY

PRECLINICAL

  • TOXICITY

  • PHARMACOKINETICS

  • FORMULATION

  • STABILITY

  • BIOLOGICAL STUDIES

PHASE I

  • DOSIFICATION

  • ADMINISTRATION

  • TOXICITY

  • PHARMACOKINETICS

  • SECURITY

PHASE II

  • EFICIENCY

  • SECURITY

  • THERAPEUTIC INDICATION

PHASE III

  • COMPARISON WITH STANDARD TREATMENTS

  • REGISTRATION: REVIEW AND APPROVAL BY HEALTH AUTHORITIES (FDA/EMEA)

 2 AND 4 YEARS

3 TO 7 YEARS

Our Results

Antitumoural

Biopharmaceutical against colon cancer

NEO-920
CC-0320
EL-0119
SM-0220

Neuro-degenerative

Biopharmaceutical 

JZ1.3
JZ1.24
JZ1.40

Hypoglycemic

ANTITUMOURAL

AE-1224

Carrier

ANTITUMOURAL

NM-0822
DDS-424

Biopharmaceutical against pancreatic cancer

N-Olaparib

9

ACTIVE INGREDIENTS

PATENTED OR LICENSED BY CELLBITEC

Our R&D Projects

Pre-clinical validation of NPS functionalised with EUPHORBIA LATHYRIX biomolecules as a novel targeted therapy for advanced CRC

Plant-based nano-pharmaceuticals with anti-tumour activity against colon cancer

Valorisation of waste derived from fruit and vegetable crops to obtain nutraceuticals active in colon cancer and metabolic syndrome.

Brassiceuticals
 
OUR R&D PROJECTS

Discover the Future

We are a biotechnology company committed to the discovery of efficient and effective bioactive principles as pharmaceuticals, nutraceuticals or useful in the field of plant biology.

Contact us